| Catalog No. | HF574016 |
|---|
| Species reactivity | Human |
|---|
| Applications | Research Grade Biosimilar |
|---|
| Host species | Humanized |
|---|
| Isotype | IgG1-kappa |
|---|
| Expression system | Mammalian Cells |
|---|
| Clonality | Monoclonal |
|---|
| Target | Sodium/phosphate cotransporter 2B, Na(+)-dependent phosphate cotransporter 2B, Na(+)/Pi cotransporter 2B, Sodium-dependent phosphate transport protein 2B, NaPi3b, NaPi-2b, SLC34A2, Solute carrier family 34 member 2, Sodium-phosphate transport protein 2B |
|---|
| Concentration | 1mg/ml |
|---|
| Endotoxin level | Please contact the lab for this information. |
|---|
| Purity | >95% purity as determined by SDS-PAGE. |
|---|
| Purification | Protein A/G, purified from cell culture supernatant. |
|---|
| Accession | O95436 |
|---|
| Form | Liquid |
|---|
| Storage buffer | 0.01M PBS,pH7.4. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -393°C. |
|---|
| Alternate Names | DNIB0600A(conjugate),MNIB2126A(nonconjugate),CAS:1615697-16-9 |
|---|
| Background | Lifastuzumab is a humanized anti-NaPi2b monoclonal antibody (IgG1 type). Lifastuzumab can be coupled with monomethyl auristatin E (MMAE) through ADC Linker to form an antibody-drug conjugate (ADC) lifastuzumab vedotin (DNIB0600A) with anticancer activity. |
|---|
| Note | For research use only. Not for use in clinical or therapeutic applications. |
|---|
